These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27226090)

  • 1. Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.
    Delaney TA; Morehouse C; Brohawn PZ; Groves C; Colonna M; Yao Y; Sanjuan M; Coyle AJ
    J Immunol; 2016 Jul; 197(1):42-50. PubMed ID: 27226090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the involvement of type I interferon in pulmonary arterial hypertension.
    George PM; Oliver E; Dorfmuller P; Dubois OD; Reed DM; Kirkby NS; Mohamed NA; Perros F; Antigny F; Fadel E; Schreiber BE; Holmes AM; Southwood M; Hagan G; Wort SJ; Bartlett N; Morrell NW; Coghlan JG; Humbert M; Zhao L; Mitchell JA
    Circ Res; 2014 Feb; 114(4):677-88. PubMed ID: 24334027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    McCormick LL; Zhang Y; Tootell E; Gilliam AC
    J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Invest Dermatol; 2016 Nov; 136(11):2158-2167. PubMed ID: 27424318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification.
    Teijaro JR; Studer S; Leaf N; Kiosses WB; Nguyen N; Matsuki K; Negishi H; Taniguchi T; Oldstone MB; Rosen H
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1351-6. PubMed ID: 26787880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablation of Type-1 IFN Signaling in Hematopoietic Cells Confers Protection Following Traumatic Brain Injury.
    Karve IP; Zhang M; Habgood M; Frugier T; Brody KM; Sashindranath M; Ek CJ; Chappaz S; Kile BT; Wright D; Wang H; Johnston L; Daglas M; Ates RC; Medcalf RL; Taylor JM; Crack PJ
    eNeuro; 2016; 3(1):. PubMed ID: 27022620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis.
    Zhang LJ
    Front Immunol; 2019; 10():1440. PubMed ID: 31293591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
    Barrat FJ; Lu TT
    Curr Opin Rheumatol; 2019 Nov; 31(6):569-575. PubMed ID: 31436583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
    Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
    Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
    Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease.
    Liu C; Yang X; Zhu P; Fujino M; Ito H; Takahashi K; Nakajima M; Tanaka T; Wang J; Zhuang J; Zou H; Li XK
    Exp Dermatol; 2018 Oct; 27(10):1104-1111. PubMed ID: 29978518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
    Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.
    Wenzel J; Lucas S; Zahn S; Mikus S; Metze D; Ständer S; von Stebut E; Hillen U; Bieber T; Tüting T
    J Am Acad Dermatol; 2008 Mar; 58(3):437-42. PubMed ID: 18280341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
    Askew D; Zhou L; Wu C; Chen G; Gilliam AC
    J Invest Dermatol; 2007 Aug; 127(8):1905-14. PubMed ID: 17429441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease.
    Kavian N; Marut W; Servettaz A; Laude H; Nicco C; Chéreau C; Weill B; Batteux F
    J Immunol; 2012 May; 188(10):5142-9. PubMed ID: 22491256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.